Visual and Anatomical Outcomes of Branch Retinal Vein Occlusion in Routine Care: A Retrospective Study of 102 Eye Records
BackgroundBranch retinal vein occlusion (BRVO) can cause visual loss through macular oedema.Routine-care outcomes reflect heterogeneous treatment histories and follow-up.This study evaluated visual and anatomical changes and their association in a district-hospital BRVO cohort. MethodsWe retrospectively analysed 102 eye records classified into 11 treatment pathways within a five-year period from January 2019 to December 2023.Visual acuity (VA), recorded in letters, and five-field average optical coherence tomography (OCT) thickness were compared between baseline and the last recorded appointment with a minimum of four weeks of follow-up.Mean changes were calculated with 95% confidence intervals (CIs).Pearson and Spearman correlations assessed the association between VA gain and OCT thickness reduction.Treatment groups were described without causal comparisons. ResultsMedian follow-up was 23 months (interquartile range, 12-38.5;range, 2-73).Mean VA increased from 60.0 ± 17.0 to 72.3 ± 13.8 letters; mean change was 12.3 ± 16.7 letters (95% CI, 9.0-15.5).Mean five-field average OCT thickness declined from 414.5 ± 109.5 to 300.5 ± 55.7 µm; mean reduction was 113.9 ± 125.2 µm (95% CI, 89.4-138.5).Forty-two eye records (41.2%) gained at least 15 letters, and four (3.9%) lost at least 15 letters.VA gain correlated with thickness reduction (Pearson r = 0.54; 95% CI, 0.38-0.66;Spearman ρ = 0.59).Exclusion of two zero-letter baseline records yielded a mean gain of 11.8 ± 16.5 letters.The aflibercept and ranibizumab categories comprised 35 and 30 records, respectively. ConclusionsVisual improvement and reduced five-field average OCT thickness were observed during routine BRVO care, with a moderate association between functional and anatomical change.Ranibizumab showed the largest mean VA gain amongst the single-agent treatment groups, exceeding the observed aflibercept.Variable follow-up, small treatment subgroups, and non-random treatment selection limit comparative interpretation.The findings support assessing vision and retinal anatomy together and do not establish superiority of any treatment pathway.
Authors
- Suki Bernstein
- Cora Berdejo
Institutions
- George Eliot Hospital (GB)
- Warwick Hospital (GB)
- Warwickshire Hospital (GB)
- George Eliot Hospital NHS Trust (GB)
Publication Details
- Journal
- Cureus
- Published
- 2026-11-14
- DOI
- https://doi.org/10.7759/cureus.119647
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00